Poster: Safety and monitoring in patients receiving casirivimab and imdevimab for COVID-19
11 January 2022
| Publication
Overview
This collection of posters are supportive tools based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, preparing, and administering the neutralizing monoclonal antibody casirivimab and imdevimab in patients with non-severe, severe, and critical COVID-19 infection.
They provide information on the following for casirivimab and imdevimab:
- Patient selection
- Dosage consideration based on disease severity
- Preparation and dilution instructions for intravenous formulation
- Preparation and administration instructions for subcutaneous formulation
- Safety and monitoring considerations
WHO Team
Health Care Readiness (HCR)